Shots:
- Organon & Samsung Bioepis have expanded their development and commercialisation agreement to commercialise a new biosimilar in Australia
- As per the deal, Organon will receive exclusive commercial rights to the biosimilar in Australia while Samsung Bioepis will be responsible for full development, manufacturing & regulatory responsibilities
- The amended agreement expands their collaboration to 4 biosimilars in Australia, broadening access to biosimilar medicines across multiple therapeutic areas
Ref: Organon | Image: Organon & Samsung Bioepis | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us atconnect@pharmashots.com
